Sanober Kable, MD
Pulmonary Disease · Denison, TXNPI 1295876399
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,656 of the $228,769 with a category attached, or 73.3%. 54 manufacturers reported payments, led by GSK at 35.8% of the total. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,577 payments — averaging $145.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$82K
- Sanofi$55K
- AstraZeneca$41K
- Jazz Pharmaceuticals Inc.$11K
- United Therapeutics Corporation$10K
- Sunovion Pharmaceuticals Inc.$9K
- plus $22K from 48 others
Across 208 payments — averaging $3281.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$389K
- United Therapeutics Corporation$67K
- AstraZeneca$57K
- Bayer$36K
- Cumberland Pharmaceuticals, Inc.$33K
- Boehringer Ingelheim$28K
- plus $73K from 6 others
What the payments were for
- Consulting fees$22,03910%
- Speaking & faculty fees$167,65673%
- Travel & lodging$8,8064%
- Food & beverage$27,16312%
- Education$3,1051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$42,911
- BREZTRI$30,604
- TRELEGY ELLIPTA$18,100
- NUCALA$10,729
- ANORO ELLIPTA$9,600
- XYWAV$9,474
- AREXVY$8,551
- LONHALA MAGNAIR$7,738
- BREZTRI AEROSPHERE$4,692
- ORENITRAM$3,810
- FASENRA$3,459
- ION$3,000
- Adempas$1,902
- Da Vinci Surgical System$1,375
- TYVASO$1,270
- remede System$1,189
- Rapiblyk$685
- ACQUIRE$684
- GLASSIA$600
- Yupelri$384
How this compares
$228,769 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 154 | $1,903,769 |
| OfevNintedanib Esylate | 141 | $1,857,554 |
| AdempasRiociguat | 117 | $1,488,016 |
| UptraviSelexipag | 40 | $1,049,254 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 884 | $879,731 |
| Tyvaso DpiTreprostinil | 24 | $551,106 |
| WinrevairSotatercept-Csrk | 21 | $356,618 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 289 | $298,149 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 28 | $281,400 |
| Dupixent PenDupilumab | 56 | $244,062 |
| XywavSodium,calcium,mag,pot Oxybate | 11 | $196,712 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $196,285 |
| Dupixent SyringeDupilumab | 39 | $191,756 |
| Orenitram ErTreprostinil Diolamine | 23 | $136,798 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $75,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,029 | $2,953,022194 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,777 | $2,005,065334 claims |
| BayerAdempas | $2,204 | $1,488,016117 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $81,808 | $925,290956 claims |
| MerckWinrevair, Dulera | $134 | $364,03733 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $40,882 | $308,481325 claims |
| Grifols USA, LLCProlastin C | $619 | $281,40028 claims |
| PfizerEliquis | $39 | $10,38616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Denison
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.